Product news

Share this article:
Cephalon has received FDA approval for Treanda (bendamustine hydrochloride), an injectable indicated for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions